Allarity Therapeutics, Inc.
ALLR
$1.13
$0.043.67%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -27.43% | 10.96% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -39.08% | 36.13% | |||
| Operating Income | 39.08% | -36.13% | |||
| Income Before Tax | -20.95% | 15.08% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -20.95% | 15.08% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -20.95% | 15.08% | |||
| EBIT | 39.08% | -36.13% | |||
| EBITDA | 39.19% | -36.23% | |||
| EPS Basic | -27.53% | 39.09% | |||
| Normalized Basic EPS | -27.55% | 39.10% | |||
| EPS Diluted | -27.53% | 39.09% | |||
| Normalized Diluted EPS | -27.55% | 39.10% | |||
| Average Basic Shares Outstanding | -5.17% | 39.44% | |||
| Average Diluted Shares Outstanding | -5.17% | 39.44% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||